Korea Q4 Roundup: Overseas Sales, M&A Provide Growth Amid General Weakness

Several major South Korean pharma firms benefited from solid sales of new drugs, and in some cases M&A deals, outside the country, although overall growth was generally weak. Meanwhile, a long-running leadership dispute at Hanmi has been resolved.